You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 7, 2025

Drug Price Trends for FT ALLERGY (CHLORPHEN)


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for FT ALLERGY (CHLORPHEN)

Average Pharmacy Cost for FT ALLERGY (CHLORPHEN)

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
FT ALLERGY (CHLORPHEN) 4 MG TB 70677-1016-01 0.01669 EACH 2025-01-22
FT ALLERGY (CHLORPHEN) 4 MG TB 70677-1016-01 0.01804 EACH 2024-12-18
FT ALLERGY (CHLORPHEN) 4 MG TB 70677-1016-01 0.01767 EACH 2024-11-20
FT ALLERGY (CHLORPHEN) 4 MG TB 70677-1016-01 0.02086 EACH 2024-10-23
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Chlorpheniramine Maleate Market Analysis and Price Projections

Introduction to Chlorpheniramine Maleate

Chlorpheniramine maleate, commonly known by brand names such as Chlor-Trimeton or Piriton, is an antihistamine medication used to treat various allergic conditions, including allergic rhinitis (hay fever), common cold, and other allergy-related symptoms. It works by blocking the action of histamine, a natural substance in the body that causes allergy symptoms like sneezing, itching, runny nose, and watery eyes[1][2][5].

Market Size and Growth Projections

The global chlorpheniramine maleate market has been experiencing steady growth, driven by several key factors.

  • Current Market Size: The market was valued at approximately $468.6 million in 2022[1] and $471 million in 2022 according to other sources[2][4].
  • Projected Market Size: It is expected to reach $751.4 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 4.9% from 2023 to 2032[1]. Alternatively, some reports project the market to reach $744 million by 2032 with a CAGR of 4.8%[2][4].

Market Drivers

Several factors are driving the growth of the chlorpheniramine maleate market:

  • Prevalence of Allergic Disorders: The increasing global incidence of allergic conditions, partly due to environmental changes and increased allergen exposure, is a significant catalyst for demand[3].
  • Accessibility and Affordability: In emerging economies, the cost-effectiveness of chlorpheniramine maleate makes it a preferred choice over more expensive, second-generation antihistamines[3].
  • Versatile Applications: Beyond allergies, chlorpheniramine maleate's use in common cold preparations underscores its versatility, sustaining its demand across diverse patient demographics[3].
  • Urbanization and Lifestyle Changes: Increase in urbanization and changes in lifestyles have been associated with a higher prevalence of allergies, boosting the market growth[1][2].

Market Segmentation

The chlorpheniramine maleate market is segmented in several ways:

  • By Application: The market is segmented into allergy, hay fever (allergic rhinitis), common cold, watery eyes, itchy throat/skin, anaphylactic shock, and urticaria. The allergy segment accounted for the largest share and is projected to exhibit the fastest market growth during the forecast period[1][5].
  • By Dosage Form: The market includes various dosage forms such as tablets, capsules, liquid formulations, and injections. The injection segment has captured a significant share of the market[2][5].
  • By Distribution Channel: The market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies have exhibited the highest growth and are anticipated to lead during the forecast period[1][2].
  • By Region: The market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the majority share in 2022 and is anticipated to remain dominant during the forecast period. The Asia-Pacific region is expected to witness the highest growth rate due to rising prevalence of allergic conditions and increasing consumer awareness[1][4][5].

Regional Analysis

  • North America: This region held more than 38% of the market share in 2022 and is expected to dominate the market during the forecast period due to advancements in healthcare infrastructure and the high prevalence of allergic conditions[1][4][5].
  • Asia-Pacific: This region is expected to experience significant growth, driven by factors such as accelerated urbanization, increasing environmental pollution, and a large patient pool requiring treatment for allergic conditions[1][4][5].

Market Challenges

Despite the growth, the market faces several challenges:

  • Side Effect Profile: Sedation and drowsiness associated with first-generation antihistamines like chlorpheniramine maleate can deter users, especially those requiring daytime alertness[3].
  • Regulatory Scrutiny: Tightening regulations regarding over-the-counter medications and their side effects pose challenges to market growth[3].
  • Competition from Advanced Antihistamines: The development of newer, non-sedating antihistamines with longer-lasting effects presents a formidable challenge, shifting preferences among a segment of consumers[3].

Key Market Players

The chlorpheniramine maleate market is competitive, with several key players:

  • Capellon Pharmaceuticals
  • Sun Pharmaceutical Industries Limited
  • Bayer AG
  • Viatris Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novalab Healthcare Pvt. Ltd.
  • Alkem Laboratories Ltd.
  • Zydus Lifesciences Limited[1].

Price Projections and Market Trends

Given the projected market growth, the prices of chlorpheniramine maleate are likely to remain competitive due to the presence of multiple manufacturers and the generic nature of the drug.

  • Cost-Effectiveness: The cost-effectiveness of chlorpheniramine maleate, especially in emerging economies, is expected to maintain its market position against more expensive alternatives[3].
  • Innovative Formulations: Continuous advancements in pharmaceutical research and the development of innovative and effective chlorpheniramine maleate formulations will help sustain market growth[4].

Key Takeaways

  • The global chlorpheniramine maleate market is expected to grow significantly, driven by the increasing prevalence of allergic conditions and the cost-effectiveness of the drug.
  • North America is anticipated to dominate the market, while the Asia-Pacific region will experience the highest growth rate.
  • The market faces challenges from side effects and competition from advanced antihistamines but is supported by its versatility and established presence in the pharmaceutical realm.

Frequently Asked Questions (FAQs)

Q: What is chlorpheniramine maleate used for? A: Chlorpheniramine maleate is used to treat various allergic conditions, including allergic rhinitis (hay fever), common cold, and other allergy-related symptoms such as sneezing, itching, runny nose, and watery eyes[1][2][5].

Q: What is the projected market size of chlorpheniramine maleate by 2032? A: The market is expected to reach $751.4 million by 2032, growing at a CAGR of 4.9% from 2023 to 2032[1].

Q: Which region dominates the chlorpheniramine maleate market? A: North America dominates the market, holding more than 38% of the market share in 2022 and expected to remain dominant during the forecast period[1][4][5].

Q: What are the main challenges facing the chlorpheniramine maleate market? A: The main challenges include the side effect profile of the drug, regulatory scrutiny, and competition from advanced antihistamines[3].

Q: Who are the key players in the chlorpheniramine maleate market? A: Key players include Capellon Pharmaceuticals, Sun Pharmaceutical Industries Limited, Bayer AG, Viatris Inc., Johnson & Johnson, and others[1].

Cited Sources

  1. Allied Market Research: Chlorpheniramine Maleate Market Statistics and Forecast - 2032[1].
  2. Acumen Research and Consulting: Chlorpheniramine Maleate Market Size USD 744 Million by 2032[2].
  3. Research and Markets: Global Chlorpheniramine Maleate Market Report and Forecast 2024[3].
  4. GlobeNewswire: Chlorpheniramine Maleate Market is forecasted to Reach USD 744 Million by 2032[4].
  5. IndustryARC: Chlorpheniramine Maleate Market - Forecast(2025 - IndustryARC[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.